Health Technology

Nucleai and GoPath Diagnostics Announce Strategic Collaboration to Provide Integrated AI-powered Digital Pathology Solutions for Clinical Research and Diagnostic Applications

Retrieved on: 
Monday, April 8, 2024
Other Health, Software, Research, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Genetics, Health Technology, Science, Biotechnology, Health, College, GCP, LMS, Algorithm, Prostate cancer, Case management, Good clinical laboratory practice, Partnership, LIMS, CLEP, Biomarker, GCLP, AI, CAP, Good clinical practice, IBD, Medicine, Workflow, CLIA, Pathology, Inflammatory bowel disease, Medical director, Medical device

Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.

Key Points: 
  • Nucleai , a spatial AI biomarker company that deciphers cellular conversations and maps cellular interactions within tissue samples to predict therapeutic outcomes, today announced a strategic collaboration with GoPath Diagnostics , a leading full-service digital pathology and molecular diagnostics laboratory.
  • This partnership unites Nucleai and GoPath's complementary skills to expedite the development of new AI-powered clinical research and diagnostics.
  • The integrated solutions will be deployed within a centralized environment that meets the standards of the College of American Pathologists (CAP), Clinical Laboratory Improvement Amendments (CLIA), Clinical Laboratory Evaluation Program (CLEP), Good Clinical Practice (GCP), and Good Clinical Laboratory Practice (GCLP).
  • Jim Lu, M.D., CEO and Medical Director for GoPath Diagnostics, said: “Our collaboration with Nucleai transforms our capabilities, enabling GoPath to deliver a seamlessly integrated lab workflow.

Bruker Introduces Novel NMR Scientific Capabilities for Structural Biology Discoveries in Membrane Proteins and Protein Aggregates

Retrieved on: 
Monday, April 8, 2024
Research, Technology, Semiconductor, Genetics, Health Technology, Nanotechnology, Biotechnology, Hardware, Health, Science, CNRS, CPMAS, 2000s, HCN, Membrane, Corporation, DNP, NMR, Bruker, Hertz, Protein, Multimedia, MAS, BRKR, WB, Medical imaging

Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.

Key Points: 
  • Bruker Corporation (Nasdaq: BRKR), the leading provider of nuclear magnetic resonance (NMR) spectroscopy solutions, announces the introduction of novel high-resolution solid-state NMR scientific capabilities that can enable unprecedented structural biology discoveries in large proteins, membrane proteins and in protein aggregates.
  • Featuring a 160 kHz Magic Angle Spinning (MAS) system, it takes high-resolution MAS and proton detection on solid biological samples to the next level, enabling new scientific discoveries.
  • The dramatically enhanced 1H-NMR resolution and enhanced T2' times make 160 kHz MAS suitable for the study of large proteins, membrane proteins and protein aggregates.
  • In addition, a 160 kHz MAS probe is now installed on the 1.0 GHz NMR at CNRS Lyon, where it expands the scientific capabilities of biological solid-state research.

Mirion Dosimetry Services Announces Availability of New InstadoseVUE Wireless Radiation Dosimeter

Retrieved on: 
Monday, April 8, 2024
Biotechnology, Health, Biometrics, Other Health, Nuclear, Radiology, Energy, Oncology, Other Science, Medical Devices, General Health, Hospitals, Health Technology, Science, Radiation, Communication, Risk, VUE, Safety, Multimedia, Medical imaging

Mirion Dosimetry Services , a Mirion Medical company, today announced commercial availability of its innovative new Instadose®VUE wireless dosimeter .

Key Points: 
  • Mirion Dosimetry Services , a Mirion Medical company, today announced commercial availability of its innovative new Instadose®VUE wireless dosimeter .
  • View the full release here: https://www.businesswire.com/news/home/20240408854096/en/
    The Instadose®VUE wireless dosimeter from Mirion Dosimetry Services, a Mirion Medical company.
  • “Launching the InstadoseVUE dosimeter signifies more than just the release of a product; it embodies our vision to redefine radiation safety in workplaces.
  • Electronic display screen for expanded user visibility, engagement, and compliance
    “The InstadoseVUE wireless dosimeter is not just for radiation workers and medical imaging personnel,” says Bart LeClou, VP of International Sales for Mirion Dosimetry Services.

Vicarious Surgical to Report First Quarter 2024 Financial Results on April 29, 2024

Retrieved on: 
Monday, April 8, 2024
Robotics, Health, Medical Devices, Technology, Surgery, Health Technology, Other Technology

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024.

Key Points: 
  • Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics company seeking to improve the cost, efficiency, and outcomes of surgical procedures, today announced it will report financial results for the first quarter ended March 31, 2024 after the market closes on Monday, April 29, 2024.
  • Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
  • Investors interested in listening to the conference call may do so by dialing +1 833 470 1428 for domestic callers or +1 404 975 4839 for international callers, using access code: 061323.
  • A live and archived webcast of the event will be available at https://investor.vicarioussurgical.com .

Consensus Cloud Solutions to Host Q1 Investor Call on May 8th, 2024

Retrieved on: 
Monday, April 8, 2024
Technology, Telecommunications, Health Technology, Software, Internet, Health, General Health, Data Management, Artificial Intelligence, Consensus, Cloud, Consensus decision-making, EVP

Consensus Cloud Solutions, Inc., (NASDAQ: CCSI), invites the public, members of the press, the financial community, and other interested parties to listen to a live audio Webcast of its Q1 earnings call at 2:00 PM PT/5:00 PM ET on Wednesday, May 8th, 2024.

Key Points: 
  • Consensus Cloud Solutions, Inc., (NASDAQ: CCSI), invites the public, members of the press, the financial community, and other interested parties to listen to a live audio Webcast of its Q1 earnings call at 2:00 PM PT/5:00 PM ET on Wednesday, May 8th, 2024.
  • Consensus Cloud Solutions’ Chief Executive Officer, Scott Turicchi, Chief Revenue Officer and EVP of Operations, Johnny Hecker, and Chief Financial Officer, Jim Malone will host the call to discuss Q1 financial results, provide an update on the business and host a live Q&A.
  • Questions for the conference call will be taken via email at [email protected] and can be sent any time prior to or during the Webcast.
  • If you are unable to attend the live Webcast, the conference call and presentation materials will be archived at https://www.investor.consensus.com/ .

SpineX Closes Recruitment for SCONE™ Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Children, Biotechnology, FDA, Health, Neurology, Health Technology, Medical Devices, Research, Consumer, Science, Clinical Trials, Cord, Brain, Cerebral palsy, Multiple sclerosis, SCIP, Patient, Stroke, Clinical trial, Urinary bladder, Trial of the century, Skin, Spinal cord, Heart, Urinary incontinence, Cauda equina syndrome, Neuromodulation, Pharmaceutical industry

SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.

Key Points: 
  • SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device.
  • The clinical trial— Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study — began in May 2022.
  • “SCONE has the power to transform the lives of millions of patients with neurogenic bladder,” says Parag Gad, SpineX co-founder & CEO.
  • SpineX anticipates beginning a multi-center pivotal trial for children with Cerebral Palsy in 2024.

Synchron Launches Patient Registry for Stentrode Brain Computer Interface

Retrieved on: 
Monday, April 8, 2024
Medical Devices, Health, Neurology, Health Technology, Other Health, Biotechnology, Brain, BCI, Motor cortex, Communication, Patient, UPMC, University, Disability studies, Movement, Physician, Pathology, Medical device

The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.

Key Points: 
  • The Synchron BCI represents a novel approach to restoring functionality in patients with limited mobility.
  • By leveraging the natural highways of the brain, an individual’s blood vessels, the device is implanted in the brain without the need for invasive brain surgery.
  • “We are thrilled to launch our community-centered BCI registry,” said Tom Oxley, CEO & Founder, Synchron.
  • For more information about the Synchron BCI and our registry, visit https://synchronbci.com .

Thermo Fisher Scientific Launches New ENERGY STAR certified TSX Universal Series ULT Freezers to Deliver Tighter Temperature Control and Faster Recovery Times

Retrieved on: 
Monday, April 8, 2024
Other Health, Research, Pharmaceutical, Sustainability, Medical Devices, Environment, Health Technology, Clinical Trials, Science, Biotechnology, Medical Supplies, Health, ACT, Temperature, Thermo Fisher Scientific, Laboratory, GMP, TSX, ULT, Multimedia, ISO, Medical device

Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.

Key Points: 
  • Building on 80 years of expertise engineering cold storage lab equipment, Thermo Fisher Scientific today introduces its newest line of high performance, ultra-low temperature (ULT) freezers.
  • With enhancements to performance, user experience and energy efficiency, the Thermo Scientific™ TSX™ Universal Series ULT Freezers seamlessly adapt to scientists’ workflows across a variety of lab settings, marking a new era in performance, reliability, and sustainability.
  • With Universal V-Drive technology, tighter control, faster recovery times, universal voltage, and an expanded setpoint range, the TSX Universal Series seamlessly adapts to diverse workflows, from high-use academic labs to longer-term storage facilities.
  • Delivering both industry leading performance and energy efficiency, the TSX Universal Series allows labs to meet their sustainability goals without sacrificing performance.

Tempus Releases New Data at AACR Showcasing Ways to Analyze Multimodal Data to Highlight Potential Therapeutic Routes for HER2-Directed Antibody-Drug Conjugates in Several Tumor Types

Retrieved on: 
Monday, April 8, 2024
General Health, Pharmaceutical, Oncology, Data Management, Biometrics, Technology, Artificial Intelligence, Genetics, Health Technology, Clinical Trials, Biotechnology, Health, HER2, Database, Prevalence, Pfizer, Intelligence, Patient, Neoplasm, NGS, ERBB2, Research, RNA, Breast, Messenger, Medicine, AACR, Research fellow, Vaccine

Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.

Key Points: 
  • Tempus, a leader in artificial intelligence and precision medicine, will present new data along with Pfizer at the AACR 2024 Annual Meeting.
  • These findings may open up potential therapeutic routes for HER2-directed antibody-drug conjugates in several tumor types.
  • In 2022, Seagen (acquired by Pfizer in December 2023) engaged Tempus to investigate cohorts of patients with HER2 RNA expression.
  • As part of the collaboration, Tempus’ computational and real-world evidence teams helped provide insights on the prevalence of HER2 expression in select solid tumors.

Talking Medicines Reports Record Revenue Bookings and Strategic Partnerships in Quarter 1, 2024

Retrieved on: 
Tuesday, April 9, 2024
Software, Data Analytics, Pharmaceutical, Health, Data Management, Health Technology, Professional Services, Technology, Intelligence, Artificial intelligence, Data science, Pharmaceutical industry

Talking Medicines, a pioneering leader in healthcare intelligence leveraging Advanced Data Science and Artificial Intelligence, is proud to announce a robust start to 2024, marked by record revenue bookings and significant advancements in its innovative platform Talking Medicines Drug-GPT.

Key Points: 
  • Talking Medicines, a pioneering leader in healthcare intelligence leveraging Advanced Data Science and Artificial Intelligence, is proud to announce a robust start to 2024, marked by record revenue bookings and significant advancements in its innovative platform Talking Medicines Drug-GPT.
  • View the full release here: https://www.businesswire.com/news/home/20240408417221/en/
    AI Generated Intelligence, Drug-GPT Powered by Talking Medicines (Photo: Business Wire)
    In the first quarter of 2024, Talking Medicines achieved significant success with its Talking Medicines Drug-GPT platform, revolutionizing access to intelligence on pharmaceutical medicine brands and disease areas.
  • Furthermore, Talking Medicines has forged strategic partnerships with both open and closed data communities, solidifying its commitment to expanding access to crucial insights.
  • "We are thrilled by the overwhelming response to Talking Medicines Drug-GPT and our strategic partnerships.